Enit

Enit is an oral prescription medication that combines the active ingredients enalapril maleate and nitrendipine. It is formulated as a tablet (strength not specified) and is marketed in the European Union. Enalapril maleate is an ACE inhibitor, while nitrendipine is a dihydropyridine calcium‑channel blocker; together they work to lower elevated blood pressure. It is intended for use under medical supervision and is not available over the counter.

Enit is indicated for the management of hypertension, particularly in patients who may benefit from combined ACE inhibition and calcium‑channel blockade. The combination can be considered when monotherapy does not achieve target blood pressure or when a dual‑mechanism approach is clinically appropriate. - Used as part of a treatment regimen for essential (primary) hypertension. - May be prescribed when blood pressure remains uncontrolled on a single antihypertensive agent. - Can be employed in patients with concomitant cardiovascular risk factors where both ACE inhibition and vasodilation are desired. - May be selected for patients who require once‑daily oral dosing for convenience.

The safety profile of Enit reflects the known effects of its two components, enalapril maleate and nitrendipine. Common adverse reactions are generally mild and transient, while serious events are less frequent but require medical attention. Common: - Cough, often dry, associated with ACE inhibition. - Headache or dizziness, especially after dose initiation. - Flushing or warmth sensation due to vasodilation. - Peripheral edema, mild swelling of ankles or feet. - Nausea or abdominal discomfort. - Fatigue or malaise. Serious: - Angioedema, characterized by swelling of lips, tongue, or airway. - Severe hypotension leading to fainting or shock.

When prescribing Enit, clinicians should evaluate patient-specific factors and monitor for conditions that may increase risk of adverse outcomes. Key precautions address renal function, electrolyte balance, and potential pregnancy exposure. - Assess renal function before initiating therapy and periodically thereafter. - Monitor serum potassium and creatinine, especially in patients with renal impairment. - Use with caution in patients with a history of angioedema or severe cough. - Avoid use during pregnancy; enalapril is contraindicated in the second and third trimesters. - Review concomitant use of potassium‑sparing diuretics or supplements to prevent hyperkalemia. - Evaluate for hepatic impairment, as nitrendipine metabolism may be affected. - Consider dose adjustment in elderly patients due to altered pharmacokinetics.

Enit may interact with several medications, influencing its efficacy or safety. Identifying and managing these interactions helps maintain optimal blood pressure control. Avoid: - Concurrent use of other ACE inhibitors or ARBs, which can increase risk of hyperkalemia and renal dysfunction. - Co‑administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that raise nitrendipine levels. - Use with non‑steroidal anti‑inflammatory drugs (NSAIDs) that may blunt antihypertensive effect and affect renal function. Use with caution: - Combination with diuretics, particularly thiazides, may enhance hypotensive response. - Concurrent potassium‑sparing diuretics or supplements may increase serum potassium. - Beta‑blockers may add to bradycardia risk when combined with nitrendipine. - Lithium therapy may have altered clearance; monitor lithium levels.